Disulfidptosis: a new target for metabolic cancer therapy
- PMID: 37101248
- PMCID: PMC10134647
- DOI: 10.1186/s13046-023-02675-4
Disulfidptosis: a new target for metabolic cancer therapy
Abstract
Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study has identified a new metabolic-related RCD known as disulfidptosis. Preclinical findings suggest that metabolic therapy using glucose transporter (GLUT) inhibitors can trigger disulfidptosis and inhibit cancer growth. In this review, we summarize the specific mechanisms underlying disulfidptosis and outline potential future research directions. We also discuss the challenges that may arise in the clinical translation of disulfidptosis research.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that the study was conducted in the absence of any business or financial relationship that could be interpreted as a potential conflict of interest.
Figures

References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical